标题
CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms
作者
关键词
-
出版物
AKTUELLE UROLOGIE
Volume -, Issue -, Pages -
出版商
Georg Thieme Verlag KG
发表日期
2020-09-24
DOI
10.1055/a-1247-4155
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ziel: 20 statt 50! Aktuelle Daten zum Zielwert der Testosteronsenkung und die Forschung hierüber seit erster „LH-RH“ (GnRH)-Analoga-Gabe an Patienten vor 40 Jahren
- (2020) Peter Hammerer et al. AKTUELLE UROLOGIE
- Frühe vs. spätere Therapie mit Abirateron plus Prednison bei chemotherapie-naiven, asymptomatischen bis mild symptomatischen Patienten mit metastasiertem CRPC nach Androgendeprivation
- (2020) Axel S. Merseburger et al. AKTUELLE UROLOGIE
- Therapie des metastasierten kastrationsresistenten Prostatakarzinoms
- (2020) G. von Amsberg et al. UROLOGE
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
- (2019) M Hussain et al. ANNALS OF ONCOLOGY
- Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen
- (2019) P. Albers et al. UROLOGE
- Androgen receptor-targeted agents in the management of advanced prostate cancer
- (2019) Bertrand Tombal LANCET ONCOLOGY
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
- (2017) A H Bryce et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
- (2015) Klaus Brasso et al. EUROPEAN UROLOGY
- Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
- (2014) Sebastian Christoph Schmid et al. ADVANCES IN THERAPY
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started